{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Amino+Acid&page=22",
    "query": {
      "intervention": "Amino Acid",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 16003,
    "total_pages": 1601,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Amino+Acid&page=23&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Amino+Acid&page=21&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T02:29:09.632Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00477815",
      "title": "Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma and Plasma Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "Stem Cell",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sargramostim (GM-CSF)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "90Y-Zevalin",
          "type": "RADIATION"
        },
        {
          "name": "111In Zevalin",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 30,
      "start_date": "2005-05-31",
      "completion_date": "2018-05-07",
      "has_results": false,
      "last_update_posted_date": "2018-05-14",
      "last_synced_at": "2026-11-19T02:29:09.632Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00477815"
    },
    {
      "nct_id": "NCT00003435",
      "title": "Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood Transplantation in Treating Patients Who Are HIV Positive and Have Hematologic Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "antiviral therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "bone marrow ablation with stem cell support",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "umbilical cord blood transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 0,
      "start_date": "1998-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-03-07",
      "last_synced_at": "2026-11-19T02:29:09.632Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003435"
    },
    {
      "nct_id": "NCT05445609",
      "title": "Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Prostate Adenocarcinoma",
        "Stage IV Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "VLP-encapsulated TLR9 Agonist CMP-001,",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2023-06-07",
      "completion_date": "2029-06-23",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-11-19T02:29:09.632Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05445609"
    },
    {
      "nct_id": "NCT03423264",
      "title": "PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Oropharyngeal Cancer",
        "HPV-Related Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Gabapentin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2018-01-22",
      "completion_date": "2022-11-08",
      "has_results": false,
      "last_update_posted_date": "2024-07-31",
      "last_synced_at": "2026-11-19T02:29:09.632Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03423264"
    },
    {
      "nct_id": "NCT02027532",
      "title": "Prevention of Infection in Closed Fractures: Cefazolin Versus Vancomycin",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Infection",
        "Closed Fractures"
      ],
      "interventions": [
        {
          "name": "Cefazolin",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Tennessee",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 430,
      "start_date": "2009-10",
      "completion_date": "2017-12",
      "has_results": false,
      "last_update_posted_date": "2018-07-11",
      "last_synced_at": "2026-11-19T02:29:09.632Z",
      "location_count": 1,
      "location_summary": "Chattanooga, Tennessee",
      "locations": [
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02027532"
    },
    {
      "nct_id": "NCT04444921",
      "title": "EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anal Basaloid Carcinoma",
        "Anal Canal Cloacogenic Carcinoma",
        "Metastatic Anal Squamous Cell Carcinoma",
        "Recurrent Anal Squamous Cell Carcinoma",
        "Stage III Anal Cancer AJCC v8",
        "Stage IV Anal Cancer AJCC v8",
        "Unresectable Anal Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 205,
      "start_date": "2020-11-17",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-18",
      "last_synced_at": "2026-11-19T02:29:09.632Z",
      "location_count": 579,
      "location_summary": "Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 381 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04444921"
    },
    {
      "nct_id": "NCT03576547",
      "title": "Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Philadelphia Chromosome Positive",
        "Recurrent Acute Lymphoblastic Leukemia",
        "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Refractory Acute Lymphoblastic Leukemia",
        "Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "t(9;22)"
      ],
      "interventions": [
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Ponatinib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2018-06-26",
      "completion_date": "2024-06-19",
      "has_results": true,
      "last_update_posted_date": "2025-05-08",
      "last_synced_at": "2026-11-19T02:29:09.632Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03576547"
    },
    {
      "nct_id": "NCT02145949",
      "title": "Mechanistic Approach to Preventing Atrophy and Restoring Function in Older Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Muscle Atrophy",
        "Quality of Life"
      ],
      "interventions": [
        {
          "name": "Essential Amino Acids (EAA)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Alanine)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Oregon",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "50 Years to 80 Years"
      },
      "enrollment_count": 80,
      "start_date": "2014-12",
      "completion_date": "2020-02",
      "has_results": true,
      "last_update_posted_date": "2024-07-23",
      "last_synced_at": "2026-11-19T02:29:09.632Z",
      "location_count": 2,
      "location_summary": "Eugene, Oregon",
      "locations": [
        {
          "city": "Eugene",
          "state": "Oregon"
        },
        {
          "city": "Eugene",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02145949"
    },
    {
      "nct_id": "NCT00564538",
      "title": "A Study of Thymoglobulin and Tacrolimus in Liver Transplant",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Liver Transplantation",
        "Liver Disease",
        "Immunosuppression"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin (rabbit)",
          "type": "DRUG"
        },
        {
          "name": "tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2007-12",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2007-11-28",
      "last_synced_at": "2026-11-19T02:29:09.632Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00564538"
    },
    {
      "nct_id": "NCT00766038",
      "title": "Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Traumatic Brain Injury"
      ],
      "interventions": [
        {
          "name": "Recombinant human Growth Hormone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 63,
      "start_date": "2008-09",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2019-11-18",
      "last_synced_at": "2026-11-19T02:29:09.632Z",
      "location_count": 3,
      "location_summary": "Bakersfield, California • Dallas, Texas",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00766038"
    }
  ]
}